Insights

Sort by:AllBlogsWhite PapersWebinarsPress Releases

CMS Announces First Drugs for Price Negotiations

Inflation Reduction Act Impacts

Identify Rare Disease Launch Archetypes to Determine Your Optimal Launch Approach

The Art and Science of Forecasting Drug Launches

Policy Briefing: Executive Order 14091

Evolving Trends in Patient Services

Navigating a Drug Launch in 2022: Part 4 – The Launch Plan

Navigating a Drug Launch in 2022: Part 3 – How to execute

Navigating a Drug Launch in 2022: Part 2 – How to Win

Navigating a Drug Launch in 2022: Part 1 – Where to Play?

5 Ways the Build Back Better Act Will Reduce Costs

Evolution of Drug Launch Strategies During Covid-19

Biosimilar Commercialization: Getting it Right in the Pharma Patent Landscape

Government Intervention into Drug Pricing: Part 4

Government Intervention into Drug Pricing: Part 3

Government Intervention into Drug Pricing: Part 2

Government Intervention into Drug Pricing: Part 1

Herspiegel Expands Market Access Support for Clients

CREATES Act Hopes to Spur Generic Competition in Pharmaceutical Market

Cigna’s Initiative to Lower the Out-Of-Pocket Cost of Insulin

Celebrating International Women’s Day

Innovative Drug Pricing via “Netflix Model”

Planning for 505(b)2 Commercial Success

Fed-Up Hospitals are Starting Their Own Drug Company to Lower Generic Drug Prices

FDA Continued Rejections of Citizen Petitions Highlights Key Lifecycle Challenges for Biologic Manufacturers

The FDA approved Dupixent for moderate-to-severe atopic dermatitis

Why Drug Pricing is in the News Now and What Can Be Done About It?

Key Challenges Facing Obamacare Repeal and Replace Plan

How Pharma Can Prepare for the Patent Cliff

Innovation in Pharma Sees Drop in 2016

Vermont Drug Price Transparency Bill

Biking for a World Without Diabetes